Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Launched by DUKE UNIVERSITY · Sep 9, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how well ablative radiotherapy, a type of focused radiation treatment, works for patients with metastatic cancer, which means the cancer has spread from its original site to other parts of the body. The study aims to gather information about any side effects that people might experience right after receiving this treatment. By creating a registry of participants, the researchers hope to better understand how this therapy can help manage cancer that has metastasized.

To participate in the trial, you must be at least 18 years old and have evidence of metastatic disease. This includes specific types of cancer spread, known as oligometastasis, where the cancer is limited to a few sites. You should also be planning to receive or have already received this specialized type of radiotherapy. There are no exclusions based on health conditions, so many patients may qualify. If you choose to participate, you'll need to sign a consent form, and throughout the study, you can expect to provide information about your treatment and any side effects you experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years of age
• • Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
• • Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
• • Patient must sign study-specific informed consent
• Exclusion Criteria:
• • • None